DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07423481

SEMAFOLLOW

Not yet recruiting

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

3,000

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Describe weight changes during the follow-up period according to patient

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07423481
Org study IDRC25_0446
Secondary ID2026-A00299-42ANSM

Timeline

Milestones

Study first posted2026-02-20actual
Last update posted2026-05-13actual
Study start2026-06-01estimated
Primary completion2027-03-01estimated
Study completion2027-03-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients treated with WEGOVY® (semaglutide 2.4 mg) under temporary authorization for use (ATU) and the early access program in France.

Inclusion criteria

•Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
•No objection to the use of their data
•Patients able to complete an online questionnaire (via the internet)

Exclusion criteria

• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Other (unclassified)
2

Weight & body composition

2 endpoints
Primary/protocol endpoint/low confidence

Describe weight changes during the follow-up period according to patient characteristics.

Time frame:Baseline

descriptive

Secondary/protocol endpoint/low confidence

Describe weight change according to different subpopulations.

Time frame:Baseline

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.

Time frame:Baseline

descriptive

Secondary/protocol endpoint/low confidence

Compare the profiles of responders and non-responders

Time frame:Baseline

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.